Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models
Abstract Neutrophil gelatinase-associated lipocalin (NGAL) is involved in cardiovascular and renal diseases. Gene inactivation of NGAL blunts the pathophysiological consequences of cardiovascular and renal damage. We aimed to design chemical NGAL inhibitors and investigate its effects in experimenta...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/586ab7e43039448a81137dea9b14ca3a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:586ab7e43039448a81137dea9b14ca3a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:586ab7e43039448a81137dea9b14ca3a2021-12-02T13:24:07ZAntifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models10.1038/s41598-021-82279-02045-2322https://doaj.org/article/586ab7e43039448a81137dea9b14ca3a2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82279-0https://doaj.org/toc/2045-2322Abstract Neutrophil gelatinase-associated lipocalin (NGAL) is involved in cardiovascular and renal diseases. Gene inactivation of NGAL blunts the pathophysiological consequences of cardiovascular and renal damage. We aimed to design chemical NGAL inhibitors and investigate its effects in experimental models of myocardial infarction (MI) and chronic kidney disease induced by 5/6 nephrectomy (CKD) on respectively 8–12 weeks old C57Bl6/j and FVB/N male mice. Among the 32 NGAL inhibitors tested, GPZ614741 and GPZ058225 fully blocked NGAL-induced inflammatory and profibrotic markers in human cardiac fibroblasts and primary mouse kidney fibroblasts. The administration of GPZ614741 (100 mg/kg/day) for three months, was able to improve cardiac function in MI mice and reduced myocardial fibrosis and inflammation. The administration of GPZ614741 (100 mg/kg/day) for two months resulting to no renal function improvement but prevented the increase in blood pressure, renal tubulointerstitial fibrosis and profibrotic marker expression in CKD mice. In conclusion, we have identified new compounds with potent inhibitory activity on NGAL-profibrotic and pro-inflammatory effects. GPZ614741 prevented interstitial fibrosis and dysfunction associated with MI, as well as tubulointerstitial fibrosis in a CKD model. These inhibitors could be used for other diseases that involve NGAL, such as cancer or metabolic diseases, creating new therapeutic options.Benjamin BonnardErnesto Martínez-MartínezAmaya Fernández-CelisMarie Pieronne-DeperroisQuoc-Tuan DoIsbaal RamosPatrick RossignolFaiez ZannadPaul MulderAntoine Ouvrard-PascaudNatalia López-AndrésFrédéric JaisserNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Benjamin Bonnard Ernesto Martínez-Martínez Amaya Fernández-Celis Marie Pieronne-Deperrois Quoc-Tuan Do Isbaal Ramos Patrick Rossignol Faiez Zannad Paul Mulder Antoine Ouvrard-Pascaud Natalia López-Andrés Frédéric Jaisser Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| description |
Abstract Neutrophil gelatinase-associated lipocalin (NGAL) is involved in cardiovascular and renal diseases. Gene inactivation of NGAL blunts the pathophysiological consequences of cardiovascular and renal damage. We aimed to design chemical NGAL inhibitors and investigate its effects in experimental models of myocardial infarction (MI) and chronic kidney disease induced by 5/6 nephrectomy (CKD) on respectively 8–12 weeks old C57Bl6/j and FVB/N male mice. Among the 32 NGAL inhibitors tested, GPZ614741 and GPZ058225 fully blocked NGAL-induced inflammatory and profibrotic markers in human cardiac fibroblasts and primary mouse kidney fibroblasts. The administration of GPZ614741 (100 mg/kg/day) for three months, was able to improve cardiac function in MI mice and reduced myocardial fibrosis and inflammation. The administration of GPZ614741 (100 mg/kg/day) for two months resulting to no renal function improvement but prevented the increase in blood pressure, renal tubulointerstitial fibrosis and profibrotic marker expression in CKD mice. In conclusion, we have identified new compounds with potent inhibitory activity on NGAL-profibrotic and pro-inflammatory effects. GPZ614741 prevented interstitial fibrosis and dysfunction associated with MI, as well as tubulointerstitial fibrosis in a CKD model. These inhibitors could be used for other diseases that involve NGAL, such as cancer or metabolic diseases, creating new therapeutic options. |
| format |
article |
| author |
Benjamin Bonnard Ernesto Martínez-Martínez Amaya Fernández-Celis Marie Pieronne-Deperrois Quoc-Tuan Do Isbaal Ramos Patrick Rossignol Faiez Zannad Paul Mulder Antoine Ouvrard-Pascaud Natalia López-Andrés Frédéric Jaisser |
| author_facet |
Benjamin Bonnard Ernesto Martínez-Martínez Amaya Fernández-Celis Marie Pieronne-Deperrois Quoc-Tuan Do Isbaal Ramos Patrick Rossignol Faiez Zannad Paul Mulder Antoine Ouvrard-Pascaud Natalia López-Andrés Frédéric Jaisser |
| author_sort |
Benjamin Bonnard |
| title |
Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| title_short |
Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| title_full |
Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| title_fullStr |
Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| title_full_unstemmed |
Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| title_sort |
antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/586ab7e43039448a81137dea9b14ca3a |
| work_keys_str_mv |
AT benjaminbonnard antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT ernestomartinezmartinez antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT amayafernandezcelis antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT mariepieronnedeperrois antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT quoctuando antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT isbaalramos antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT patrickrossignol antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT faiezzannad antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT paulmulder antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT antoineouvrardpascaud antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT natalialopezandres antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels AT fredericjaisser antifibroticeffectofnovelneutrophilgelatinaseassociatedlipocalininhibitorsincardiacandrenaldiseasemodels |
| _version_ |
1718393150502862848 |